Search Within

Robert Motzer

Formats
  1. Journal Article (610)
  2. Meeting Abstract (580)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (4)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1252)
  2. Genitourinary Oncology Service (1252)
  3. Solid Tumor Oncology Division (1252)
  4. Surgery (292)
  5. Urology (283)
  6. Survivorship Research (254)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (35)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Oxford University Press (112)
  3. Elsevier Science, Inc. (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (87)
  6. American Association for Cancer Research (58)

More Publishers

Results (1252)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
    Journal Article

    Rini, B. I.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape
    Journal Article

    Golkaram, M.; Kuo, F.; Gupta, S.; Carlo, M. I.; Salmans, M. L.; Vijayaraghavan, R.; Tang, C.; Makarov, V.; Rappold, P.; Blum, K. A.; more...
    Genome Medicine (2022)

    Fulltext@MSK | Save
  • Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade
    Journal Article

    Ged, Y.; Sanchez, A.; Patil, S.; Knezevic, A.; Stein, E.; Petruzella, S.; Weiss, K.; Duzgol, C.; Chaim, J.; Akin, O.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study
    Meeting Abstract

    Voss, M. H.; Powles, T.; McGregor, B. A.; Porta, C.; Grünwald, V.; Merchan, J. R.; Rolland, F.; Maroto-Rey, P.; Goh, J. C.; Xing, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER
    Meeting Abstract

    Suárez, C.; Choueiri, T. K.; Burotto, M.; Powles, T.; Bourlon, M. T.; Shah, A. Y.; Tomita, Y.; Bedke, J.; Zhang, J.; Simsek, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N)
    Meeting Abstract

    Shah, N. J.; Shinde, R.; Moore, K.; Sainski-Nguyen, A.; Le, L.; Cao, F.; Song, R.; Singhal, P.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience
    Meeting Abstract

    Saliby, R. M.; Jammihal, T.; Labaki, C.; Xie, W.; Motzer, R. J.; Powles, T.; Rini, B. I.; Albiges, L.; Pal, S. K.; McKay, R. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer
    Meeting Abstract

    Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Molecular profile and clinical outcomes of renal cell carcinoma brain metastases treated with stereotactic radiosurgery
    Meeting Abstract

    Ma, J.; del Balzo, L.; Khaleel, S. S.; Flynn, J.; Zhang, Z.; Voss, M. H.; Freeman, B.; Hakimi, A. A.; Lee, C. H.; Eichholz, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC
    Meeting Abstract

    Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save